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Abstract
Alterations of mitochondrial DNA copy number (mtDNAcn) in the blood (mitochondrial to
nuclear DNA ratio) appear associated with several systemic diseases, including primary
mitochondrial disorders, carcinogenesis, and hematologic diseases. Measuring mtDNAcn
in DNA extracted from whole blood (WB) instead of from peripheral blood mononuclear
cells or buffy coat may yield different results due to mitochondrial DNA present in platelets.
The aim of this work is to quantify the contribution of platelets to mtDNAcn in whole blood
[mtDNAcn(WB)] and to propose a correction formula to estimate leukocytes’ mtDNAcn
[mtDNAcn(L)] from mtDNAcn(WB). Blood samples from 10 healthy adults were combined
with platelet-enriched plasma and saline solution to produce artificial blood preparations.
Aliquots of each sample were combined with five different platelet concentrations. In 46 of
these blood preparations, mtDNAcn was measured by qPCR. MtDNAcn(WB) increased
1.07 (95%CI 0.86, 1.29; p<0.001) per 1000 platelets present in the preparation. We proved
that leukocyte count should also be taken into account as mtDNAcn(WB) was inversely
associated with leukocyte count; it increased 1.10 (95%CI 0.95, 1.25, p<0.001) per unit
increase of the ratio between platelet and leukocyte counts. If hematological measure-
ments are available, subtracting 1.10 the platelets/leukocyte ratio from mtDNAcn(WB) may
serve as an estimation for mtDNAcn(L). Both platelet and leukocyte counts in the sample
are important sources of variation if comparing mtDNAcn among groups of patients when
mtDNAcn is measured in DNA extracted from whole blood. Not taking the platelet/leukocyte
ratio into account in whole blood measurements, may lead to overestimation and misclassi-
fication if interpreted as leukocytes’ mtDNAcn.
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Introduction
Mitochondria are intracellular organelles involved in energy production through the process of
oxidative phosphorylation (OXPHOS) that have their own genome (mtDNA), distinct from
that in the cell nucleus (nDNA). Although the mitochondrial mass per cell varies with cell type
and metabolic state, each cell type typically contains a fairly constant amount of mitochondria
and accordingly, the number of copies of the mitochondrial genome is also constant, as it is
linked to mitochondrial mass[1]. Each mitochondrion contains between 2 and 10 copies of its
genome[2]. High-energy requiring cells, such as muscle and neurons, contain a large number
of mtDNA copies, while low-energy requiring cells, such as spleen and endothelial cells, con-
tain fewer copies[3–5]. The amount of mtDNA per cell, or mtDNA copy number (mtDNAcn),
can be expressed as a ratio of mtDNA to nDNA copies, i.e. using nDNA as reference, assuming
that all quantified cells are nucleated and diploid[6]. Nowadays, quantitative real-time PCR
(qPCR) is a suitable method to quantify mtDNAcn[7–9].
Either reduction or increase in the biogenesis or availability of mitochondria in the cells
may be markers of primarymitochondrial pathology or of systemic pathology that affects
mitochondrial biology. AlthoughmtDNAcn can be studied in any tissue, blood is one of the
most commonly used, as samples can be easily obtained. Alterations of mtDNAcn in the blood
may be associated to primarymitochondrial disorders[10,11], which are sometimes associated
to primary genetic mutations[12,13], but have also been linked to cardiac dysfunction[14], car-
cinogenesis and cancer progression[15,16], HIV infection[17,18], diabetes[19–21], and micro-
albuminuria[22].
For the study of mtDNAcn, DNA is usually obtained from peripheral bloodmononuclear
cells (PBMC). In such samples, platelet contamination may lead to overestimation of
mtDNAcn measurements[23] since one platelet contains around 1.6 molecules of mtDNA on
average but no nuclear DNA[24]. Timmermans et al.[18] reported that contaminating platelets
did not influence the results if their total number is below 5 times the number of PBMC. Most
large-scale epidemiological studies have DNA samples available, but in many cases they have
been extracted from whole blood and not from PBMC[25–27]. Healthy subjects usually have
14–90 times more platelets than leukocytes in peripheral blood[28]. Therefore, a pool of
PBMCs’, granulocytes’, and platelets’ mtDNA is present in those samples, which could affect
mtDNAcn quantification. In fact, many studies have been performed using mtDNAcn data
measured in whole blood, and although they were able to establish associations with morbid
processes such as cancer[15,16], non-Hodgkin lymphoma[29,30], Huntington's disease[31],
diabetes[19–21], and microalbuminuria[22], considering the effect of platelets could improve
the discovery process.
The aims of this work are to describe the effect of platelet count in mtDNAcn in whole
blood, to evaluate the extent of mtDNAcn overestimation and misclassification on real epide-
miological data, and to propose a correction formula to estimate leukocytes’ mtDNAcn
[mtDNAcn(L)] from whole bloodmtDNAcn [mtDNAcn(WB)], if hematological measure-
ments of the original sample are available.
Materials and Methods
Design
MtDNAcn was measured in several artificial blood preparations that were experimental combi-
nations of blood samples with platelet-enriched plasma and saline solution so that each sample
was combined with five different platelet concentrations. The coefficients that relate hemato-
logical parameters with mtDNAcn, according to a theoretical formulation framework, were
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estimated statistically. Afterwards,mtDNAcn data from an observational study was used to
describe the differences in value and subject classification between raw mtDNAcn measure-
ments in whole blood and values corrected to approximate mtDNAcn(L) using the previously
estimated coefficients.
Samples
Fasting whole blood samples from 10 randomly selected (8 men and 2 women) participants of
the AragonWorkers’ Health Study[32] whose complete blood count was inside healthy ranges
were used to produce the artificial blood preparations for the experiments. The samples were
collected in 6 ml EDTA-K2 tubes (BD Vacutainer). The AragonWorkers’ Health Study,
AWHS, is a longitudinal study of healthy middle-agedworkers in a large car factory in Spain,
and data from the whole cohort with available mtDNAcn (N = 3389) was used to compare
mtDNAcn(WB) and calculatedmtDNAcn(L). All participants were informed about the
AWHS and the potential research uses of their samples and they signed a written informed
consent approved by the Clinical Research Ethics Committee of Aragon (CEICA).
Experimental protocol
After measuring blood cells count, each participant’s sample was processed to obtain 5 derived
artificial blood preparations, so that each one contained a different proportion of leukocytes
and platelets. DNA was subsequently extracted from the original samples and the derived prep-
arations, and mtDNAcn was measured in the extractedDNA.
Blood preparations
For each participant, six 50 μl aliquots of whole bloodwere created and reserved. From the rest
of the sampled blood, platelets were isolated to obtain platelet-enriched plasma. In brief, blood
was centrifuged at 100 x g for 15 min at room temperature. The upper layer was transferred
into a new tube and was centrifuged once more at 200 x g for 10 min at room temperature.
This supernatant, containing the platelets (platelet enriched plasma, PEP), was saved to be
combined in different proportions with saline solution (Table 1) and it was added to five of the
whole blood reserved aliquots. Blood counts were obtained from the preparations. Samples
and preparations were kept at -80°C until DNA extraction.
Blood count
Blood samples and preparations were analyzed in a COULTER ACT 5diff analyzer (Beckman
Coulter) to determine platelet and leukocyte counts. Internal quality controls of three levels
were measured before the daily work. An external quality control from the Spanish Association
of Pharmaceutical Analysts (AEFA) was processed every 4-months.
Table 1. Proportions for the blood preparations.
Preparation number
P1 P2 P3 P4 P5
Blood (μl) 50 50 50 50 50
Saline solution (μl) 400 387.5 350 200 0
Platelet-enriched plasma (PEP) (μl) 0 12.5 50 200 400
Ratio of PEP volume with respect to P2 - 1x 4x 16x 32x
doi:10.1371/journal.pone.0163770.t001
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DNA extraction and Quantitative Polymerase Chain Reaction assays for
mtDNA
For the experimental part, DNA was extractedmanually from the blood samples and blood
preparations with phenol-chloroform, according to the protocol describedby Marcuello et al.
[33]. Concentration and purity of DNA were measured with a Nanovue spectrophotometer
(Thermo Fisher Scientific,USA) and DNA dilutions at 2 ng/μl were prepared for the analyses.
For the AWHS cohort samples, DNA was extracted with the AutoGenFlex 3000 extractor,
using the FlexiGeneDNA kit (Qiagen), which is based on alcoholic precipitation. Similarly,
DNA dilutions at 2 ng/μl were prepared for the subsequent mtDNAcn measurement.
Quantification of mtDNAcn relied on quantitative real-time polymerase chain reactions
(qPCR) based on SYBR Green assays and performed in an ABI PRISM17900 Real-Time PCR
System (Applied BioSystems). In a single 384-well reaction plate, two sets of 10 μl reactions
were performed in separate reaction wells, one for the mitochondrial cytochrome oxidase II
gene (MT-CO2), and one for the nuclear gene for the A subunit of succinate dehydrogenase
(SDHA), producing amplicons of 69 and 72 bp respectively. Each reaction contained 5 ng of
DNA and 400 nM of each primer. Primer sequences and positions are indicated in Table A in
S1 File. The samples as well as a negative control and a 7-point 1:10 dilution curve of a standard
(describedbelow) were analyzed in triplicate. Conditions used for amplification were as fol-
lows: one cycle of 50°C for 2 min, one cycle of 95°C for 10 min, 40 cycles of 95°C for 1 sec. and
60°C for 20 sec., one cycle of 60°C for 15 sec and 1 cycle of 95°C for 15 sec. To accommodate
all the measurements in a single reaction plate we measured only 46 out of the 50 preparations
(we left out four P3 preparations).
The standard curve, which contained an equal number of copies for both amplicons (see
below), was used as a reference for absolute quantification of each gene using the threshold
cycle number (Cq) method. The thresholds were obtained by the default second derivate
method on ABI PRISM (SequenceDetection System, SDS 2.4 software). The ratio of the abso-
lute quantity ofMT-CO2 to that of SDHA (mtDNA copy number—mtDNAcn) was used as a
measurement of half of the number of copies of mtDNA in leukocytes.We use the term
mtDNAcn(WB) to refer to the direct (uncorrected)measurements performed in whole blood
samples or blood preparations in contrast to mtDNAcn(L) which would be obtained from
measuring in leukocytes or derived with our correction formula (see below).
Standard
A PCR standard was created by ligating one copy of the amplicon forMT-CO2 and one copy of
the amplicon for SDHA[34]. A longer amplicon (224 bp) for theMT-CO2 gene (Table A in S1
File), which included the region used for qPCR determination, was used to allow an adequate
discrimination of the correct ligation products after PCR amplification. The sequence of the
PCR standard was verified by Sanger sequencing. The standard was prepared by performing
six 10-fold dilutions from an initial concentration of 0.1ng/μl.
Formulation framework
In whole blood, the number of copies of mtDNA (nmtDNA) is the sum of the number of copies
of mtDNA per leukocyte (mtDNAL) multiplied by the count of leukocytes (nL) plus the number
of copies of mtDNA per platelet (mtDNAP) multiplied by the count of platelets (nP).
nmtDNA ¼ mtDNAL  nL þmtDNAP  nP
Similarly, the number of copies of nDNA (nnDNA) is the number of copies of nDNA per
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leukocyte (nDNAL), assuming 2 in diploid cells (nDNAL = 2), multiplied by the count of leuko-
cytes (nL).
nnDNA ¼ nDNAL  nL
The ratio of mtDNA (mtDNAcn) is calculated by dividing the number of copies of mtDNA




and nDNAL ¼ 2;
in whole blood,












ReplacingmtDNAcn(L) appropriately, we obtain:











¼ K represents the factor that multiplies the ratio between platelets and leu-
kocyte counts to calculate the excess value ofmtDNAcn(WB) with respect tomtDNAcn(L). We
estimated the factor (K) by means of a statistical model:
mtDNAcn WBð Þ  b0 þ b1 
nP
nL
in which estimating β0 will provide an estimation formtDNAcn(L), assumed constant for
our samples, and estimating β1 will provide an estimation for K ¼ mtDNAP2 .
Thus, the formula that we propose for correctingmtDNAcn(WB) is:




Data are presented as mean and standard deviation (SD). All statistical analyses were per-
formed with the statistical package R (version 3.0.2)[35]. The coefficients for the association
between leukocytes and platelets with mtDNAcn(WB) were determined using linear regression
analysis. We built multivariate regression models to determine the effect of platelet and leuko-
cyte counts on mtDNAcn(WB). We first modeled the association betweenmtDNAcn(WB)
and platelets count; then we performedmodels to determine to what extent the inverse of leu-
kocyte count was a confounding factor or an effectmodifier, so as to check whether empirical
data matched our formulation framework. Given that our 46 preparations were originated
from 10 samples we verified our estimation using multilevel mixed-effectsmodels: a model
with common slope and random intercept terms (model 1), one with correlated random
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intercept and slope (model 2), and one with uncorrelated random intercept and slope (model
3). The statistical significance threshold was set at p<0.05.
We calculatedmtDNAcn(L) frommtDNAcn(WB) for the AWHS participants using our
correction formula. We described the mean, standard deviation and percentiles, as well as
cross-classification of participants in quintiles of both values. We report the percentage of par-
ticipants that were classified in a different quintile by each value.
Results
The hematological values of the primary samples used for the experiment were within normal
limits (Table 2). In them, the mean (standard deviation) of mtDNAcn(WB) was 97.22 (28.24).
In the blood preparations supplemented with different amounts of platelet-enriched plasma
(46 data points), mtDNAcn(WB) increased 1.01 (95%CI 0.84, 1.17; p<0.001) per μl of platelet-
enriched plasma added (Fig 1). The mtDNAcn(WB) increased 1.07 (95%CI 0.86, 1.29;
p<0.001) per 103 platelets and it also showed an inverse association with leukocyte count
(Table 3).
We built multivariate regression models to evaluate the influence of the platelets and leuko-
cytes on mtDNAcn(WB), and we found a significant interaction between platelets and 1/leuko-
cytes that was the only statistically significant term in that model for mtDNAcn(WB)(Table 3),
consistent with the correction term that our formulation identified as determinant of the
mtDNAcn(WB)(See Formulation framework). According to our formulation framework, with
a simple regression model (Table 3 - Model 6) we estimated that mtDNAcn(WB) changed 1.10
(95%CI 0.95, 1.25, p<0.001) per unit increase of the platelets/leukocyte ratio (Fig 2). We also
estimated this influencewith multilevel models, which took into account the structure of our
Table 2. Hematological results from primary blood samples (n = 10) that were used to derive blood preparations.
Mean Standard Deviation(SD) Minimum value Maximum value
White Blood Cells (103/μL) 7.56 1.76 5.3 10.8
Red Blood Cells (106/μL) 4.72 0.38 4.02 5.4
Hemoglobin (g/dL) 14.82 1.16 13 17
Hematocrit (%) 43.98 3.47 38.2 50.3
Mean Cell Volume (fL) 93.2 3.58 88 100
Mean Cell Hemoglobin (pg) 31.46 1.02 29.7 33.3
Mean Corpuscular Hemoglobin Concentration (g/dL) 33.71 0.27 33.2 34
Red Cell Distribution Width (%) 12.61 0.58 11.7 13.4
Platelet count (103/μL) 234.1 38.23 190 295
Mean Platelet Volume (fL) 9.25 0.37 8.6 9.9
Plateletcrit (%) 0.37 0.48 0.17 1.75
Platelet Distribution Width (fl) 15.59 1.2 13 16.5
Neutrophils (%) 50.22 5.28 42.3 59.3
Lymphocytes (%) 39.72 5.08 33.1 48.9
Monocytes (%) 6.68 1.19 4.8 8.2
Eosinophils (%) 2.49 0.59 1.2 3.2
Basophils (%) 0.89 0.32 0.6 1.5
Abnormal Lymphocytes (%) 1.09 0.44 0.5 2
Immature Cells (%) 0.69 0.18 0.4 1
mtDNAcn(WB) 97.22 28.24 54.29 149.6
mtDNAcn(WB): mitochondrial DNA copy number in whole blood
doi:10.1371/journal.pone.0163770.t002
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Fig 1. MtDNAcn(WB) of blood preparations supplemented with different amounts of platelet-enriched plasma and saline solution.
All preparations combined 50 uL of blood, plus platelet-enriched plasma and additional saline solution to reach a volume of 450 uL. Each
box corresponds to a different combination (p1—p5, see Table 1) and summarizes data from 10 preparations (one from each original blood
sample) except in p3 (50 uL of platelet-enriched plasma), which only summarizes 6 preparations. Altogether, data from 46 preparations are
shown. Individual mtDNAcn(WB) for each preparation are plotted as white circles.
doi:10.1371/journal.pone.0163770.g001
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experiment (preparations derived from 10 different samples), and all models yielded similar
coefficients (Table B in S1 File).
In the AWHS study (n = 3389) mtDNAcn(WB) was 68.25 (SD: 15.37) being higher in
women than men and the ratio platelets/leukocytes, 33.08 (SD: 9.94) (Table 4). After applying
the correction formula with a K factor of 1.1, as calculated from the analysis above, the cor-
rectedmtDNAcn(L) was 31.86 (SD: 17.6)(Table 4). In addition, the mtDNAcn quintile of each
participant is different depending on whetherWB or L value is used (Table C in S1 File).
Indeed, 54% of participants are classified in a different quintile by each measurement (although
only 15% are classified in quintiles farther away than the neighboring one), suggesting that
each parameter conveys different information, and, given the procedure used to calculate
mtDNAcn(L), we presume that this measurement will be less dependent on hematological
parameters.
Discussion
In our study, mtDNAcn was measured in whole blood as the ratio betweenmtDNA and
nDNA using quantitative real-time polymerase chain reaction (qPCR) to study the influence of
platelet count on mtDNAcn. We compared five sets of artificial blood preparations with differ-
ent platelet concentrations and observed that the mtDNAcn did not only depend on platelet
count but also on the platelets/leukocytes ratio.
We found a significant influence of the number of platelets on mtDNAcn quantification.
Similarly, Banas et al.[36] and Andreu et al.[37] found significantly different values when
mtDNAcn was measured in whole bloodwith respect to the measurements performed in
PBMCs and buffy coat. Urata et al.[24] showed that platelet contamination, a technical limita-
tion of PBMCs separation, caused large overestimation errors and acted as a source of varia-
tion: average±SD mtDNAcn measured in 11 samples of PBMCs decreased from 269±51 to 146
±14 after platelet depletion through washing.
The main step forward in our study with respect to previous approaches[23,24,36,37] to the
problems derived from the presence of platelets is that we introduce leukocyte count as an
essential factor to take into account and contextualize this knowledge for measuringmtDNAcn
in whole blood. Dealing with platelets contamination of PBMC samples, Timmermans et al.
highlighted that when the number of contaminant platelets surpassed five times the number of
Table 3. Coefficients of multivariate regression models for mtDNAcn(WB) measured in blood preparations (n = 46).
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Platelets (change per 103 platelets) 1.07* 1.14* 1.15* -0.76
Leukocytes (change per 103 leukocytes) -132.8 -283.00*
1/Leukocytes (change per 1/103 leukocytes) 225.08* 21.02
Platelets/Leukocytes (change per ratio unit) 1.79* 1.10*
The table cells show the coefficients of the predictors in the left column.
*p < 0.001, otherwise p > 0.05
Model 1: mtDNAcn(WB) modeled from platelets count
Model 2: mtDNAcn(WB) modeled from leukocytes count
Model 3: mtDNAcn(WB) modeled from platelets and leukocyte counts
Model 4: mtDNAcn(WB) modeled from platelets count and 1/leukocytes
Model 5: mtDNAcn(WB) modeled from platelets count, 1/leukocytes and their interaction (which matches the correction term of the formulation framework)
Model 6: mtDNAcn(WB) modeled from platelets/leukocytes (correction term of the formulation framework)
mtDNAcn: mitochondrial DNA copy number, WB: whole blood
doi:10.1371/journal.pone.0163770.t003
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Fig 2. Scatter plot of the change of mtDNAcn(WB) per unit increase of the platelets/leukocyte ratio. This scatter plot shows the change of
mtDNAcn(WB) per unit increase of the platelets/leukocyte ratio. Data from 46 preparations are shown. Individual mtDNAcn(WB) for each
preparation are plotted as white circles. The line represents the fit of a linear model (see Table 3, Model 6). mtDNAcn(WB): mitochondrial DNA
copy number measured in whole blood.
doi:10.1371/journal.pone.0163770.g002
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cells in the sample, measuredmtDNAcn differed from that read on pure PBMC samples[18].
The experiment added platelets to PBMC in fixed ratios and pursued the description of a rea-
sonable threshold for contamination. The approach emphasized that leukocyte count plays a
role in the bias introduced by platelets. That safe threshold for ignoring platelets’ influence is
not an option for measurements based on whole bloodwhere platelets are usually 30 times the
number of leukocytes. Thus, a correction formula is needed for the platelet bias in whole blood
mtDNAcn measurements.
Knez et al. measuredmtDNAcn in buffy coat in a sample of Flemish population to describe
correlations with clinical variables[38]. Consistently with the mathematics of mtDNAcn(WB)
which also affects measurements in buffy coat, this study found that after age and sex, the most
outstanding clinical variables that correlated with mtDNAcn were platelets count and leuko-
cyte count, the latter with an inverse relationship. The authors concluded that future epidemio-
logical studies should adjust for these variables. Nonetheless, in that study leukocyte count was
interpreted as a measurement of systemic inflammation which accordingly opened questions
on the association of inflammation with mtDNAcn. This justifies the urgent need to clarify the
nature of mtDNAcn(WB) vs. that of mtDNAcn(L) and to provide means to factor out associa-
tions arising purely from blood composition, like our proposed formula.
MtDNAcn has been analyzed in whole blood in several clinical situations: chronic diseases
such as breast cancer, diabetes mellitus or Huntington´s disease were associated with mtDNA
depletion[16,19,30], while others such as non-Hodgkin lymphomas were associated with
mtDNA increase[29,30]. It is essential to discriminate whether the clinical associations found
in studies performed in whole blood depend on truemodifications of the mtDNAcn(L) or on
the hematological modifications that may be associated with each disease. Given that in epide-
miological studies whole blood is one of the most available samples, we have proposed a correc-
tion formula in order to estimate mtDNAcn(L) frommtDNAcn(WB). We applied this
correction to AWHS data, showing that mtDNAcn(WB) doubles estimated mtDNAcn(L).
This ratio of differences is similar to those reported by Andreu et al.[37] and Urata et al.[24].
The latter also described a decrease in mtDNAcn variability, that we do not observe, but Ura-
ta’s study was based on 11 samples while we applied our correction in thousands. In addition,
we showed that a non-ignorable amount of the observedmtDNAcn(WB) variation might be
due to the differences in hematological values among subjects, as they were classified in differ-
ent quintiles depending on the measurement used and this might hamper finding the biological
and clinical meanings of mtDNAcn if platelets and leukocyte counts are ignored, supporting
the use of the correction formula when only whole-bloodderivedDNA is available. Moreover,
several studies reported differences in mtDNA copy number betweenwomen and men. Lee
et al.[39] showed higher peripheral bloodmtDNA copy number in healthy young women
Table 4. Platelet count, Leukocyte count and mtDNAcn(WB) distributions in all subjects from the AWHS cohort study (n = 3389).
Overall (n = 3389) Male (n = 3136) Female (n = 252)
Mean SD P5 P50 P95 Mean SD P5 P50 P95 Mean SD P5 P50 P95
Platelets count (103/μL) 231.16 54.68 152 227 324 229.72 53.9 152.00 224.00 322.00 248.97 61.04 152.40 247.50 354.00
Leukocytes count (103/μL) 7.34 1.96 4.74 7.00 11.00 7.37 1.95 4.80 7.10 11.00 7.05 2.03 4.40 6.80 11.10
Platelets/Leukocytes 33.08 9.94 19.20 31.88 51.55 32.74 9.75 19.17 31.62 50.63 37.32 11.21 20.55 36.85 57.24
mtDNAcn(WB) 68.25 15.37 46.54 66.43 95.54 67.97 15.35 46.50 66.14 95.16 71.68 15.32 47.46 71.48 99.54
mtDNAcn(L) 31.86 17.6 5.37 31.06 60.84 31.96 17.59 5.37 31.06 60.86 30.63 17.75 5.35 30.73 59.64
mtDNAcn: mitochondrial DNA copy number, WB: whole blood, L: leukocytes, SD: standard deviation, P5: percentile 5th, P50: percentile 50th, P95:
percentile 95th
doi:10.1371/journal.pone.0163770.t004
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compared with men. Recently, Knez et al.[38] reported the same sex difference in general pop-
ulation using buffy coat without platelet depletion. According to our findings, these differences
could be partly explained by hematological differences by sex, like the higher number of plate-
lets that women have[40] and further analysis of these sex differences on mtDNAcn taking
hematology into account might be clarifying.
In addition to this formula that allows correction for platelet presence in the original sam-
ple, there are several aspects that still need to be standardized in the technique of mtDNAcn
measurement. Currently, methods for mtDNAcn quantification vary across laboratories and
there are several pre-analytical and analytical factors that can affect the final measurement:
sample conservation before DNA extraction, time between blood drawing and cell separation,
anticoagulant used, DNA extractionmethod, PCR inhibitors, and DNA quantificationmethod
[37]. Until standardization of these variables is achieved, reference values should be established
for each measurement protocol and study results should be compared and combined only with
extreme caution.
The experimental design allowed comparing several platelet concentrations in preparations
derived from blood from the same subject effectively factoring out biological variability to a
great extent. Thus, most of the variation observed could be considered technical variation.
Therefore, the effective sample size is 46, with data for 5 experimental conditions with 10 repli-
cas (preparations) for almost each condition. These results are a starting point for further
expanding this knowledge that will require measuring also natural variation in the platelets
and leukocytes counts and mtDNAcn. Those measurements will need the evaluation of a larger
sample, as well as double measurements of mtDNAcn in both leukocytes and/or PBMCs and
whole blood. This work also has some limitations: Our formula estimates mtDNAcn in blood
leukocytes as a whole, which include PBMCs and granulocytes and because of that the estima-
tions cannot be interpreted as a direct replacement of PBMCs’ mtCNDcn.We did not do the
parallel extraction of leukocytes and/or PBMCs, which would have provided more details in
this regard. Also, DNA extractionwas accomplished from the preparations, which were not
regular blood, but 1/9 dilutions (Table 1), but this is unlikely to have affected the results as
DNA was normalized in concentration after extraction. The range of platelets/leukocytes in the
artificial preparations spanned from 20 to 450 while the normal physiological range of this
ratio only includes the lower tail of that range. Finally, the AWHS study did not extract leuko-
cytes and/or PBMCs samples so we could only estimate the potential benefit in bias correction
using our proposed formula, but not verify the formula itself.
Conclusions
In conclusion, both platelet and leukocyte counts from the sample are important for comparing
the mtDNA content between different patients whenmtDNA copy number is estimated from
whole blood. Not taking the platelet/leukocyte ratio into account may lead to overestimation of
leukocytemtDNA content and misclassification, which may obscure the meaning of its varia-
tion as the non-corrected value depends on hematological differences to a non-ignorable
extent. We propose a correction formula that may be used to mitigate this problem. This for-
mula's coefficients are not final and future research will help in refining and validating them.
Supporting Information
S1 File. Supplemental Data. Table A, qPCR primers sequences.Table B,Multilevel mixed-
effectmodels for mtDNAcn(WB) measured in blood preparations (n = 46). MODEL 1: Com-
mon slope and random intercept (per sample) MODEL 2: Correlated random intercept and
slope (per sample) MODEL 3: Uncorrelated random intercept and slope (per sample)
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